Clinical breast cancerPub Date : 2026-11-01Epub Date: 2026-11-06DOI: 10.1016/j.clbc.2026.10.001
Alyssa Victoria Francis, Marie-France Savard, Terry L. Ng, John Hilton, Lisa Vandermeer, Mark Clemons, Sharon F. McGee
{"title":"Evaluating Physician Perspectives on Neoadjuvant Immunotherapy and Chemotherapy for Early-Stage Triple-Negative Breast Cancer","authors":"Alyssa Victoria Francis, Marie-France Savard, Terry L. Ng, John Hilton, Lisa Vandermeer, Mark Clemons, Sharon F. McGee","doi":"10.1016/j.clbc.2026.10.001","DOIUrl":"10.1016/j.clbc.2026.10.001","url":null,"abstract":"<div><h3>Purpose</h3><div>The KEYNOTE-522 trial established neoadjuvant chemo-immunotherapy as standard of care for early-stage triple-negative breast cancer (TNBC). However, questions remain regarding the optimal chemotherapy backbone and treatment-related toxicities.</div></div><div><h3>Methods</h3><div>A cross-sectional, multi-center survey was distributed to physicians responsible for prescribing systemic therapy for patients with breast cancer across Canada. Questions addressed prescribing practices prior to and following the KEYNOTE-522 protocol, areas of clinical uncertainty, and interest in future clinical trials.</div></div><div><h3>Results</h3><div>The overall response rate was 33% (50/150). Of the respondents, 36 were eligible to complete the survey, based on the screening question (72%). Despite 83.3% (30/36) stating they had adopted the KEYNOTE-522 chemotherapy backbone, 53% (19/36) frequently applied modifications, including the use of dose-dense doxorubicin/cyclophosphamide (50%, 18/36), 6-weekly pembrolizumab (50%, 18/36) and the omission of carboplatin in the setting of advanced age, poor performance status or toxicity concerns (31%, 11/36). Toxicity concerns (39%, 14/36) and schedule impracticality (25%, 9/36) were primary drivers for KEYNOTE-522 protocol deviations. While 86% (31/36) reported prescribing pembrolizumab for stage II/III TNBC, 50% (18/36) would also offer it for Stage I disease. Optimal adjuvant treatment practices also remain uncertain: 61% (22/36) reported insufficient data for the use of adjuvant capecitabine or olaparib for residual disease, while 39% (14/36) reported insufficient data for continuing pembrolizumab after pathologic complete response. All respondents indicated a need for more response-adapted regimens.</div></div><div><h3>Conclusion</h3><div>Despite the rapid adoption of neoadjuvant immunotherapy for early-stage TNBC, modifications to improve tolerability and clinical efficiency are common. Further trials to optimize outcomes and reduce toxicities are needed.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 11","pages":"Pages 58-65"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149349472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical breast cancerPub Date : 2026-11-01Epub Date: 2026-10-02DOI: 10.1016/j.clbc.2026.09.012
Pavnesh Kumar, Tanun Jitwatcharakomol, Jonathan E. Schoenhals, Sierra J. Daniel, Mariella Mestres-Villanueva, Yevgeniya Gokun, Thamilini Pathmarajah, Therese Y. Andraos, Rebekah Young, Jacob M. Eckstein, Julia R. White, Jose G. Bazan Jr, Erin Healy, Sachin R. Jhawar, Sasha J. Beyer
{"title":"Feasibility and Outcomes of Concomitant Boost in Prone Hypofractionated Whole-Breast Irradiation Using 3D-Conformal Radiotherapy","authors":"Pavnesh Kumar, Tanun Jitwatcharakomol, Jonathan E. Schoenhals, Sierra J. Daniel, Mariella Mestres-Villanueva, Yevgeniya Gokun, Thamilini Pathmarajah, Therese Y. Andraos, Rebekah Young, Jacob M. Eckstein, Julia R. White, Jose G. Bazan Jr, Erin Healy, Sachin R. Jhawar, Sasha J. Beyer","doi":"10.1016/j.clbc.2026.09.012","DOIUrl":"10.1016/j.clbc.2026.09.012","url":null,"abstract":"<div><h3>Background</h3><div>Adjuvant radiation after breast-conserving surgery (BCS) reduces recurrence and improves survival in early breast cancer. While hypofractionated whole-breast irradiation (WBI) is standard, use of a concomitant boost (CB) remains limited. We report outcomes using moderately hypofractionated WBI with CB (HFRT-CB) delivered in the prone position with 3D conformal radiation therapy (3D-CRT).</div></div><div><h3>Materials and Methods</h3><div>Following institutional review board approval, records of patients with early-stage, node-negative invasive breast cancer, or ductal carcinoma in situ treated with BCS and HFRT-CB in prone position were retrospectively reviewed. The whole breast received 40 Gy with a CB 48 Gy to the lumpectomy cavity, delivered in 15 fractions. Outcomes included ipsilateral breast tumor recurrence (IBTR), disease-free survival (DFS), local recurrence-free survival (LRFS), and overall survival (OS). Toxicities were graded using CTCAE v4.0, and physician-reported cosmesis using the Harvard Cosmetic Scale.</div></div><div><h3>Results</h3><div>A total of 393 patients, with a median age of 60, were treated prone between February 2013 and March 2025. Median follow-up was 39 months. At 3 and 5 years, DFS was 98.5% and 97.6%, and LRFS was 99.6% and 98.8%, respectively. IBTR rates were 0.4% and 1.2%. OS was 97.7% and 94.6%, with a 5-year breast cancer–specific survival of 98.8%. One patient (0.3%) had grade 3 acute toxicity; no grade ≥ 3 late toxicities occurred. Good/excellent cosmesis was reported in 96.2% at 1 year and 88.5% at 3 years.</div></div><div><h3>Conclusion</h3><div>Prone HFRT-CB with 3D-CRT offers excellent tumor control, minimal toxicity, and favorable cosmesis, supporting its use as a safe and efficient adjuvant option after BCS.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 11","pages":"Pages 66-73"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical breast cancerPub Date : 2026-11-01Epub Date: 2026-09-10DOI: 10.1016/j.clbc.2026.09.004
Gianluca Vanni, Marco Pellicciaro, Marco Materazzo, Marco Bernini, Oreste Claudio Buonomo
{"title":"Beyond the Small Incision: The Value of Endoscopic and Robotic Mastectomy.","authors":"Gianluca Vanni, Marco Pellicciaro, Marco Materazzo, Marco Bernini, Oreste Claudio Buonomo","doi":"10.1016/j.clbc.2026.09.004","DOIUrl":"10.1016/j.clbc.2026.09.004","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":"e20-e22"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Immunomodulatory Effect of Various Anesthetic Factors and Techniques on Patients Undergoing Breast Cancer Surgery: A Systematic Review and Meta-analyses of RCTs.","authors":"Paraskevas Mavropoulos, Georgios Konstantis, Georgia Tsaousi, Sofia Baka, Varvara Ziaka, Vasilis-Spyridon Tseriotis, Zoi Tsimtsiou, Chryssa Pourzitaki","doi":"10.1016/j.clbc.2026.09.002","DOIUrl":"10.1016/j.clbc.2026.09.002","url":null,"abstract":"<p><p>Breast cancer is the most common type of cancer among women, while several factors seem to play a role in carcinogenesis. Recent findings suggest that some anesthetic factors and techniques contribute to immune suppression and metastasis, while others have beneficial effects. The aim of this meta-analysis is to identify the overall effects of different anesthetic modalities on the patients' immune system after breast cancer surgery. A systematic search was conducted from February 2026 to March 2026 in PubMed, CENTRAL, and Scopus. Only Randomized controlled trials were included. As primary endpoints were considered CD4+ T cell, CD8+ T cell, and Natural killer (NK) cell counts at 24, 48, and 72 hours after the end of the surgery. As secondary endpoints were considered, Leucocytes, Lymphocytes, Neutrophils, the Neutrophil- to- Lymphocyte ratio (NLR), CD4+/CD8+, IL-2, IL-6, Matrix metalloproteinase-9 at the same time points. Sixteen studies met the inclusion criteria. We concluded in positive effects of the combination of general anesthesia (GA) and regional anesthesia on CD4+ T cells (Standardized mean difference (SMD) 0.35 [0.06; 0.64], I<sup>2</sup> 38.7%), NK cells (SMD 0.40 [0.05; 0.75], I<sup>2</sup> 56%), and NLR (SMD -0.42 [-0.64; -0.19], I<sup>2</sup> 0%) 24 hours after surgery. Also, the comparison between total intravenous anesthesia and inhalational anesthesia revealed a statistically significantly higher total leukocyte count in the inhalational anesthesia group (SMD 0.61 [0.19; 1.03], I<sup>2</sup> 0%). Combined regional and GA exerts a beneficial effect regarding NK cell counts, CD4+ T cell counts, and NLR (PROSPERO: CRD42024564788).</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":"e4-e19"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical breast cancerPub Date : 2026-11-01Epub Date: 2026-11-10DOI: 10.1016/j.clbc.2026.10.004
Elizabeth A Skelly, Eleanor Stevenson, Michaela Tsai, Dina Gordon, Kathy Trotter
{"title":"Increasing Specialty Menopause Referrals for Premenopausal Breast Cancer Patients: A Quality Improvement Initiative.","authors":"Elizabeth A Skelly, Eleanor Stevenson, Michaela Tsai, Dina Gordon, Kathy Trotter","doi":"10.1016/j.clbc.2026.10.004","DOIUrl":"10.1016/j.clbc.2026.10.004","url":null,"abstract":"<p><strong>Background: </strong>Premenopausal women with hormone receptor-positive breast cancer often develop severe menopausal symptoms from chemotherapy and endocrine therapy, reducing quality of life (QoL) and contributing to early treatment discontinuation. Referral to specialty menopause care remains inconsistent. This project evaluated whether an interdisciplinary educational intervention, combined with a structured referral pathway to a specialty menopause care clinic, could improve provider confidence and increase referrals.</p><p><strong>Methods: </strong>The project was conducted at the Swedish Gynecology Specialty Center and Swedish Breast Medical Oncology Clinic. Oncology providers and menopause-certified gynecology clinicians participated in a 60-minute hybrid workshop addressing menopause management and referral processes. Pre- and post-intervention surveys assessed provider awareness and comfort. Referral volume was tracked across Baseline (January-April 2025), Early Implementation (April-October 2025), and Post-Implementation (October 2025-January 2026).</p><p><strong>Results: </strong>Referrals increased from 22 (6.8/mo) at baseline to 104 (27.3/mo) post-implementation, representing a fourfold increase. Early implementation referrals (17.3/mo) suggested increased awareness contributed to uptake. Provider awareness of menopausal and sexual health issues rose from 80% to 100%, and comfort discussing these symptoms increased by 14%-16%. Patient surveys (n = 23) revealed a high symptom burden, including sleep disturbance (82%) and hot flashes (77%). Most patients (87.5%) found the specialty clinic helpful, and 95.7% intended to complete their endocrine therapy.</p><p><strong>Conclusion: </strong>An interdisciplinary educational intervention with a structured referral pathway significantly improved provider confidence and increased menopause specialty referrals. Integrating menopause expertise into oncology care is feasible and may enhance symptom management, treatment adherence, and QoL.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 11","pages":"83-91"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical breast cancerPub Date : 2026-11-01Epub Date: 2026-10-07DOI: 10.1016/j.clbc.2026.10.003
Giuseppe Curigliano, Luís Castelo-Branco, Volkmar Müller, Nadia Harbeck
{"title":"2026 Key European Guideline Changes for Metastatic Breast Cancer and Their Impact on Practice—Commentary Based on a Virtual Focus Group","authors":"Giuseppe Curigliano, Luís Castelo-Branco, Volkmar Müller, Nadia Harbeck","doi":"10.1016/j.clbc.2026.10.003","DOIUrl":"10.1016/j.clbc.2026.10.003","url":null,"abstract":"<div><div>The treatment landscape for metastatic breast cancer continues to evolve rapidly, driven by advances in targeted therapies and biomarker-directed treatment decisions. The European Society for Medical Oncology Living Guidelines framework allows for timely updates reflecting emerging evidence, with the 2026 update representing significant changes across all breast cancer subtypes. An expert panel was assembled to discuss key modifications from the Living Guidelines version 1.2 to the 2026 update, examining supporting clinical trial evidence and practice implications. In hormone receptor (HR)-positive, HER2-negative disease, guidelines now distinguish endocrine-sensitive from endocrine-resistant populations, with mandatory <em>PIK3CA</em> testing in the latter and expanded biomarker-driven second-line options. For HER2-positive disease, the antibody-drug conjugate (ADC) trastuzumab deruxtecan plus pertuzumab emerges as a first-line option alongside the established taxanes-trastuzumab-pertuzumab regimen, with selection guided by disease characteristics and prior therapy. Maintenance options have also expanded, including tucatinib added to dual HER2-targeted therapy or palbociclib added to HER2-targeted therapy and endocrine therapy for HR-positive/HER2-positive disease. In triple-negative breast cancer, ADCs now move into first-line therapy for both programmed death-ligand 1 (PD-L1)-positive and PD-L1-negative/immunotherapy-ineligible populations. These advances create new implementation challenges, including comprehensive biomarker testing requirements, adverse event management necessitating multidisciplinary collaboration, and educational needs spanning the entire healthcare team. This article synthesizes expert perspectives on navigating these guideline changes, addressing barriers, and identifying unanswered questions. Successful guideline implementation requires coordinated efforts in education, infrastructure development, and adaptive strategies tailored to regional resources and expertise.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 11","pages":"Pages 74-82"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149349471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical breast cancerPub Date : 2026-11-01Epub Date: 2026-09-12DOI: 10.1016/j.clbc.2026.09.006
Chi Zhang, Lin Zhou, Lingfeng Tang, Zijian Wang, Shunbo Li, Yimei Tang, Chunxiang Tian MSc, Zeyu Liu BSc, Shengchun Liu PhD
{"title":"Early On-Treatment Ultrasound Tumor Shrinkage and HER2-Positive Residual Invasive Disease After Neoadjuvant Therapy: A 2-Center Study","authors":"Chi Zhang, Lin Zhou, Lingfeng Tang, Zijian Wang, Shunbo Li, Yimei Tang, Chunxiang Tian MSc, Zeyu Liu BSc, Shengchun Liu PhD","doi":"10.1016/j.clbc.2026.09.006","DOIUrl":"10.1016/j.clbc.2026.09.006","url":null,"abstract":"<div><h3>Background</h3><div>Residual invasive disease after neoadjuvant therapy (NAT) may differ in human epidermal growth factor receptor 2 (HER2) status from the pretreatment tumor. We evaluated whether early ultrasound response adds information for estimating HER2-positive residual invasive disease at surgery beyond baseline factors.</div></div><div><h3>Patients and Methods</h3><div>This retrospective 2-center study included women with nonmetastatic HER2-positive breast cancer treated with NAT and surgery. HER2-positive residual invasive disease was the primary endpoint; pathological complete response (pCR) and HER2-negative residual invasive disease formed the comparison group. The clinical model included nodal stage, estrogen receptor expression, pretreatment tumor size, baseline HER2 immunohistochemistry, treatment intensity, and timing of HER2-directed therapy. The dynamic model additionally included tumor shrinkage after 2 cycles. Performance was assessed by bootstrap correction, repeated cross-validation, and an external supportive cohort.</div></div><div><h3>Results</h3><div>Of 815 development-cohort patients, 224 had HER2-positive residual invasive disease; 26 of 83 external-cohort patients had this outcome. Median shrinkage was 40.8% for pCR, 27.8% for HER2-negative residual disease, and 18.5% for HER2-positive residual disease. Each 10-percentage-point greater shrinkage was associated with lower odds of HER2-positive residual invasive disease (odds ratio, 0.763; 95% confidence interval, 0.708-0.823). Repeated cross-validated area under the curve increased from 0.667 to 0.736; the external dynamic-model area under the curve was 0.874. Within residual disease, the increase was modest (0.634-0.656).</div></div><div><h3>Conclusion</h3><div>Early ultrasound tumor shrinkage provided incremental risk information, but phenotype-specific discrimination was modest. Prospective evaluation is required before model estimates guide management.</div></div>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 11","pages":"Pages 48-57"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149285497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Clinical breast cancerPub Date : 2026-11-01Epub Date: 2026-09-11DOI: 10.1016/j.clbc.2026.09.005
Zeina Ayoub, Lara Hilal, Malek Safa
{"title":"Re-excision in Ductal Carcinoma In Situ: Comment on Dorten et al., \"Re-excision in Ductal Carcinoma In Situ Is Not Associated With Improved Local Control\".","authors":"Zeina Ayoub, Lara Hilal, Malek Safa","doi":"10.1016/j.clbc.2026.09.005","DOIUrl":"10.1016/j.clbc.2026.09.005","url":null,"abstract":"","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":"e23-e24"},"PeriodicalIF":2.7,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gustavo Nader Marta, Liêvin Matos Rebouças, Priscilla Furtado Souza Pasquinelli, Harley Francisco de Oliveira, Maria Carolina Lopes Perdigão, Guilherme Rocha Melo Gondim, Roberta Kramer Guedes Calixto da Silva, Rodrigo de Morais Hanriot, Mariana Paranhos Alvarenga, Gustavo Pereira Maciel, Leticia Hernandes de Brito, Rafael Lopes de Oliveira, Naira Dos Santos Gutierrez, Emily Tonin da Costa, Vitória Silva Garcia, Samir Abdallah Hanna
{"title":"Ultra-Hypofractionation in Breast Cancer: A Multicenter Retrospective Cohort Study in Brazil.","authors":"Gustavo Nader Marta, Liêvin Matos Rebouças, Priscilla Furtado Souza Pasquinelli, Harley Francisco de Oliveira, Maria Carolina Lopes Perdigão, Guilherme Rocha Melo Gondim, Roberta Kramer Guedes Calixto da Silva, Rodrigo de Morais Hanriot, Mariana Paranhos Alvarenga, Gustavo Pereira Maciel, Leticia Hernandes de Brito, Rafael Lopes de Oliveira, Naira Dos Santos Gutierrez, Emily Tonin da Costa, Vitória Silva Garcia, Samir Abdallah Hanna","doi":"10.1016/j.clbc.2026.10.011","DOIUrl":"https://doi.org/10.1016/j.clbc.2026.10.011","url":null,"abstract":"<p><strong>Background: </strong>Ultra-hypofractionated radiotherapy (UHRT) for breast cancer (BC; 26 Gy in five fractions) is non-inferior to 15-fraction regimens. However, real-world data from Latin America (LATAM) remain limited. This study evaluated the feasibility, safety, and outcomes of UHRT in Brazil.</p><p><strong>Patients and methods: </strong>Retrospective multicenter cohort included women with histologically confirmed BC treated with UHRT between December 2019 and December 2021 across public and private institutions. Primary endpoint was locoregional recurrence-free survival (LRFS). Secondary endpoints included overall survival (OS) and acute and late toxicities (CTCAE v5.0). Logistic regression assessed predictors of side effects.</p><p><strong>Results: </strong>A total of 460 patients were analyzed (median age, 65 years). Most had early-stage disease (stage 0-II: 93%) and underwent breast-conserving surgery (98.9%). The majority received 26 Gy in five daily fractions (90.4%). Median follow-up was 47.0 months (95% CI, 45.0-51.0). The 5-year LRFS was 100% for stage 0 and 99.7% (95% CI, 97.6-100) for stage I-II, with only three locoregional recurrences. The 5-year OS was 100% for stage 0 and 94.1% (95% CI, 87.8-97.2) for stage I-II. Acute grade 1-2 skin side effect occurred in 24.4% of patients, and no grade ≥3 events were observed. Late side effects were mild and infrequent, mainly grade 1 induration (3.5%) and telangiectasia (0.9%). No clinical or dosimetric factors were associated with increased side effect.</p><p><strong>Conclusions: </strong>UHRT achieved excellent local control, survival, and safety across diverse Brazilian settings, confirming its feasibility and supporting its adoption as a cost-effective and equitable standard of care for early-stage BC in LATAM.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 12","pages":"21-28"},"PeriodicalIF":2.7,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Guan-Qiao Li, Qiao Li-Pan Ye Kemu, Xi-Zong He, Juan Zhou, San-Gang Wu
{"title":"Differential Impact of Postoperative Radiotherapy on Survival Across Clinical Treatment Score Post-5 Years Risk Categories in Early-Stage Luminal Breast Cancer After Breast-Conserving Surgery.","authors":"Guan-Qiao Li, Qiao Li-Pan Ye Kemu, Xi-Zong He, Juan Zhou, San-Gang Wu","doi":"10.1016/j.clbc.2026.10.007","DOIUrl":"https://doi.org/10.1016/j.clbc.2026.10.007","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the role of Clinical Treatment Score post-5 years (CTS5) in stratifying post-operative radiotherapy (PORT) benefits in patients with T1-2N0, estrogen receptor-positive breast cancer (BC) after breast-conserving surgery (BCS).</p><p><strong>Methods: </strong>We included patients whose survival duration ≥ 60 months using the data from the Surveillance, Epidemiology, and End Results database. The association between CTS5 and survival was assessed.</p><p><strong>Results: </strong>A total of 23504 patients were included. The majority of patients (n = 19334, 82.3%) were classified as low CTS5, 3792 (16.1%) as intermediate CTS5, and 378 (1.6%) as high CTS5. The low CTS5 group exhibited significantly superior BCSS (P < .001) and OS (P < .001) than the intermediate and high CTS5 groups. While CTS5 was confirmed as an independent prognostic factor for breast cancer-specific survival (BCSS) and overall survival (OS), its interaction with PORT efficacy was paradoxical. Contrary to the hypothesis that higher-risk patients would derive the greatest benefit, the survival advantage of PORT was predominantly observed in the low CTS5 group, where PORT significantly improved both BCSS (P = .004) and OS (P < .001). Conversely, in patients with intermediate and high CTS5 scores, PORT did not confer a significant benefit regarding BCSS or OS.</p><p><strong>Conclusions: </strong>CTS5 serves as a robust independent prognostic indicator and a cost-effective tool for risk stratification. The benefit of PORT in early-stage BC is most pronounced in low CTS5 patients. These findings highlight the potential of CTS5 as a stratification tool for identifying differential PORT benefit, although its role in prospectively guiding PORT selection requires validation.</p>","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":"26 12","pages":"13-20"},"PeriodicalIF":2.7,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}